{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:25:24Z","timestamp":1787027124639,"version":"build-2736575974"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bullous pemphigoid (BP) and atopic dermatitis (AD) are chronic inflammatory skin diseases that may share overlapping immunopathogenic mechanisms, particularly a type 2 immune response. Emerging evidence suggests that dupilumab, an IL-4R\u03b1 antagonist, may be effective in treating both conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective case series, twelve patients (mean age: 78.6\u00a0years; range: 67\u201393\u00a0years) with moderate to severe BP and a history of AD were included. All patients received dupilumab and were monitored over 12\u00a0weeks. Clinical activity was assessed using BPDAI scores, pruritus NRS, and DLQI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At week 12, complete remission of bullous skin lesions was observed in all patients (100%), with 83.3% already achieving this by week 4. Pruritus improved significantly (p &amp;lt; 0.0001), with 58.3% achieving complete resolution (NRS 0\/10) at week 12. Notably, two patients had previously received tralokinumab without clinical improvement, underscoring the distinct efficacy of dupilumab in this setting. Patient satisfaction was uniformly high (score 5\/5). No adverse events were reported. Dupilumab was well tolerated, even in elderly, multimorbid patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dupilumab appears to be a safe and highly effective treatment for patients with concurrent BP and AD, leading to rapid and sustained symptom control, resolution of skin lesions, and high patient satisfaction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1656089","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T05:45:17Z","timestamp":1756446317000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Dupilumab in patients with bullous pemphigoid and concomitant atopy"],"prefix":"10.3389","volume":"16","author":[{"given":"Katerina","family":"Jobst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan R.","family":"K\u00fcnzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Beissert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series","volume":"83","author":"Abdat","year":"2020","journal-title":"J. Am. Acad. Dermatology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/bjd.18958","article-title":"Implementation of dupilumab in routine care of atopic eczema: results from the German national registry TREAT Germany","volume":"183","author":"Abraham","year":"2020","journal-title":"Br. J. Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.abd.2024.08.008","article-title":"Efficacy and safety of dupilumab in patients with moderate-to-severe bullous pemphigoid: a systematic review and meta-analysis","volume":"100","author":"Da Silva","year":"2025","journal-title":"An. Bras. Dermatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in adults and Adolescents with eosinophilic esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.2340\/00015555924447","article-title":"Diagnostic Features of atopic dermatitis","volume":"60","author":"Hanifin","year":"1980","journal-title":"Acta Derm. Venereol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/ddg.15046","article-title":"Autoimmune bullous dermatoses","volume":"21","author":"Holtsche","year":"2023","journal-title":"J. Dtsch. Derma Gesell"},{"key":"B8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40257-023-00832-1","article-title":"Advancements in bullous pemphigoid treatment: a Comprehensive Pipeline Update","volume":"25","author":"Karakioulaki","year":"2024","journal-title":"Am. J. Clin. Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12016-007-0030-y","article-title":"The Pathophysiology of bullous pemphigoid","volume":"33","author":"Kasperkiewicz","year":"2007","journal-title":"Clin. Rev. Allerg. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fmed.2018.00220","article-title":"The growing incidence of bullous pemphigoid: overview and potential Explanations","volume":"5","author":"Kridin","year":"2018","journal-title":"Front. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/ced\/llad331","article-title":"Rapid and sustained response to tralokinumab in a patient with severe bullous pemphigoid and end-stage kidney disease","volume":"49","author":"Maglie","year":"2024","journal-title":"Clin. Exp. Dermatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"adv43667","DOI":"10.2340\/actadv.v105.43667","article-title":"Time to disease control with dupilumab for bullous pemphigoid: a systematic review and meta-analysis","volume":"105","author":"Mainville","year":"2025","journal-title":"Acta Derm. Venereol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1590\/abd1806-4841.20199007","article-title":"Bullous pemphigoid","volume":"94","author":"Miyamoto","year":"2019","journal-title":"An. Bras. Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1007\/s12325-024-02810-3","article-title":"Study design of a phase 2\/3 Randomized controlled trial of dupilumab in Adults with bullous pemphigoid: LIBERTY-BP ADEPT","volume":"41","author":"Murrell","year":"2024","journal-title":"Adv. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/534314a","article-title":"Can you teach old drugs new tricks?","volume":"534","author":"Nosengo","year":"2016","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/jdv.17094","article-title":"Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real\u2010life study","volume":"35","author":"Patruno","year":"2021","journal-title":"Acad. Dermatol Venereol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e13190","DOI":"10.1111\/dth.13190","article-title":"Targeting interleukin 4 receptor \u03b1: a new approach to the treatment of cutaneous autoimmune bullous diseases?","volume":"33","author":"Russo","year":"2020","journal-title":"Dermatol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.3390\/jcm11123367","article-title":"Use of dupilumab in bullous pemphigoid: where are We Now?","volume":"11","author":"Russo","year":"2022","journal-title":"JCM"},{"key":"B20","volume-title":"Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD","year":"2025"},{"key":"B21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/exd.13416","article-title":"Eosinophils as putative therapeutic targets in bullous pemphigoid","volume":"26","author":"Simon","year":"2017","journal-title":"Exp. Dermatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"824110","DOI":"10.3389\/fimmu.2022.824110","article-title":"IL-13 Genetic Susceptibility to bullous pemphigoid: a potential target for treatment and a prognostic marker","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1165106","DOI":"10.3389\/fimmu.2023.1165106","article-title":"Anti-interleukin 4 receptor \u03b1 antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: a monocentric real-world study","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jaad.2024.04.026","article-title":"Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay registry","volume":"91","author":"Zhang","year":"2024","journal-title":"J. Am. Acad. Dermatology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamadermatol.2023.2428","article-title":"Evaluation of dupilumab in patients with bullous pemphigoid","volume":"159","author":"Zhao","year":"2023","journal-title":"JAMA Dermatol"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1656089\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T05:45:17Z","timestamp":1756446317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1656089\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":26,"alternative-id":["10.3389\/fphar.2025.1656089"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1656089","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"article-number":"1656089"}}